The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 2: Psoriasis

May 17, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Guselkumab (Tremfya):24 injection

Drug class: Monoclonal antibody, IL-23-RA

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
Explore This Issue
May 2019
Also By This Author
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare

Warnings & Precautions

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Serious infections have occurred. Guselkumab may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue the drug until the infection resolves.
  • Prior to initiating treatment with secukinumab, evaluate for TB.

Dosage & Administration

Guselkumab is administered by subcutaneous injection. The recommended dose is 100 mg at Week 0, Week 4, and every eight weeks thereafter.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Commentary: Guselkumab was the first biologic approved that selectively blocks IL-23. It received FDA approval based on results from a clinical development program that included more than 2,000 patients. The most common adverse reactions (≥1%) are upper respiratory infections, headache, injection site reactions, arthralgias, diarrhea, gastroenteritis, tinea infections and herpes simplex infections.

Tildrakizumab-asmn (Ilumya):25 injection

Drug class: Monoclonal antibody, IL-23-RA

Warnings & Precautions

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Hypersensitivity: If a serious allergic reaction occurs, discontinue tildrakizumab-asmn immediately and initiate appropriate therapy.
  • Serious infections have occurred. Guselkumab may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue the drug until the infection resolves.
  • Prior to initiating treatment with tildrakizumab-asmn, evaluate for TB.

Dosage & Administration

Tildrakizumab-asmn is administered by subcutaneous injection. The recommended dose is 100 mg at Weeks 0 and 4, and every 12 weeks thereafter.

Commentary: The FDA approval was based on results from two clinical trials that enrolled 926 patients. There was significant improvement in patients who received tildrakizumab-asmn 100 mg compared with placebo. The most common adverse reactions (≥1%) are upper respiratory infections, injection site reactions, and diarrhea.


Mary Choy, PharmD, BCGP, FASHP, is a medical writer and editor living in New York City. She is the director of pharmacy practice for the New York State Council of Health-System Pharmacists.

References

  1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029–1072.
  2. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729–735.
  3. Patryk K, Marcinkiewicz K, Bergler-Czop B, et al. How does stigma affect people with psoriasis? Postepy Dermatol Alergol. 2017 Feb;34(1):36–41.
  4. Zschocke I, Ortland C, Reich K. Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1014:1020.
  5. Poelman S, Keeling CP, Metelitsa AI, et al. Practical guidelines for managing patients with psoriasis on biologics: an update. J Cutan Med Surg. 2019 Jan/Feb;23(1_suppl):3S–12S.
  6. The National Psoriasis Foundation. Financial assistance resource center.
  7. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073–1113.
  8. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5–32.
  9. FDA website. Otezla prescribing information. 2017 Jun.
  10. FDA website. Humira prescribing information. 2018 Dec.
  11. FDA website. Amjevita prescribing information. 2018 Mar.
  12. FDA website. Cyltezo prescribing information. 2017 Aug.
  13. FDA website. Hyrimoz prescribing information. 2018 Oct.
  14. FDA website. Cimzia prescribing information. 2019 Feb.
  15.  FDA website. Enbrel prescribing information. 2018 May.
  16. FDA website. Remicade prescribing information. 2018 Jun.
  17. FDA website. Inflectra prescribing information. 2018 Jul.
  18. FDA website. Renflexis prescribing information. 2019 Mar.
  19. FDA website. Ixifi prescribing information. 2017 Dec.
  20. FDA website. Stelara prescribing information. 2018 Jun.
  21. FDA website. Siliq prescribing information. 2017 Feb.
  22. FDA website. Taltz prescribing information. 2018 May.
  23. FDA website. Cosentyx prescribing information. 2018 Jan.
  24. FDA website. Tremfya prescribing information. 2019 Jan.
  25. FDA website. Ilumya prescribing information. 2018 Mar.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, apremilast, brodalumab, Certolizumab Pegol, etanercept, guselkumab, guttate psoriasis, infliximab, inverse psoriasis, ixekizumab, Psoriatic Arthritis, psoriatic erythroderma, pustular psoriasis, Rheumatic Drugs at a Glance, secukinumab, tildrakizumab, ustekinumab, vulgar psoriasisIssue: May 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)